PMID- 20230463
OWN - NLM
STAT- MEDLINE
DCOM- 20101130
LR  - 20191210
IS  - 1540-8159 (Electronic)
IS  - 0147-8389 (Linking)
VI  - 33
IP  - 7
DP  - 2010 Jul
TI  - Adrenomedullin plasma levels predict left ventricular reverse remodeling after 
      cardiac resynchronization therapy.
PG  - 865-72
LID - 10.1111/j.1540-8159.2010.02723.x [doi]
AB  - BACKGROUND: Increase in adrenomedullin (ADM) plasma levels in congestive heart 
      failure (HF) patients is due to many cardiac and systemic factors, particularly 
      to greater fluid retention and to activation of sympathetic nervous system. Aim 
      of this study was to assess the role of plasma ADM levels in HF patients treated 
      by cardiac resynchronization therapy (CRT). METHODS: 50 patients, mean age 70 
      years, 34 male, New York Heart Association (NYHA) Class III-IV HF, left 
      ventricular ejection fraction (LVEF) < 35%, underwent CRT. All patients were in 
      sinus rhythm and with complete left bundle branch block (QRS duration 138 +/- 6 
      msec). A complete echoDoppler exam, blood samples for brain natriuretic peptide 
      (BNP), and ADM were obtained from 2 to 7 days before implantation. RESULTS: At 16 
      +/- 6 months follow-up, >or=1 NYHA Class improvement was observed in 38 patients. 
      However, a >10% reduction in end-systolic dimensions (ESD) was reported in 21 
      patients (Group I): -16.6 +/- 1.8%; in the remaining 29 patients ESD change was 
      almost negligible: -2.0 +/- 1.03% (Group II), P < 0.0001. The two groups were 
      comparable for age, sex, cause of LV dysfunction, therapy, QRS duration at 
      baseline, preimplantation ESD, LVEF%, and BNP. Significantly higher pre 
      implantation ADM levels were present in Group I than in Group II (27.2 +/- 1.8 
      pmol/l vs 17.9 +/- 1.4, P = 0.0003). CONCLUSIONS: Significantly higher ADM levels 
      indicate a subgroup of patients in whom reverse remodeling can be observed after 
      CRT. Patients with lower ADM basal values before CRT could represent a group in 
      whom the dysfunction is so advanced that no improvement can be expected.
FAU - Morales, Maria-Aurora
AU  - Morales MA
AD  - CNR Institute of Clinical Physiology and G. Monasterio Foundation, Pisa, Italy. 
      morales@ifc.cnr.it
FAU - Maltinti, Maristella
AU  - Maltinti M
FAU - Piacenti, Marcello
AU  - Piacenti M
FAU - Turchi, Stefano
AU  - Turchi S
FAU - Giannessi, Daniela
AU  - Giannessi D
FAU - Del Ry, Silvia
AU  - Del Ry S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20100308
PL  - United States
TA  - Pacing Clin Electrophysiol
JT  - Pacing and clinical electrophysiology : PACE
JID - 7803944
RN  - 0 (Biomarkers)
RN  - 148498-78-6 (Adrenomedullin)
SB  - IM
MH  - Adrenomedullin/*blood
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Cardiac Pacing, Artificial/*methods
MH  - Female
MH  - Heart Failure/blood/*diagnosis/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care/methods
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/blood/*diagnosis/*prevention & control
MH  - Ventricular Remodeling
EDAT- 2010/03/17 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/03/17 06:00
PHST- 2010/03/17 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - PACE2723 [pii]
AID - 10.1111/j.1540-8159.2010.02723.x [doi]
PST - ppublish
SO  - Pacing Clin Electrophysiol. 2010 Jul;33(7):865-72. doi: 
      10.1111/j.1540-8159.2010.02723.x. Epub 2010 Mar 8.